Claims about PresVu eye drop false, unethical: DCGI
Explanation sought from pharma firm
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Advertisement
The claims made by ENTOD Pharmaceuticals that its product PresVu eye drops had been approved by Drug Controller General of India (DCGI) and that the drug offered spectacular treatment for presbyopia were unethical and false presentation of facts, a top official source said. A DGCI official said an explanation had been sought from the company.
“This is unethical and false presentation of facts. Explanation has been sought from the company,” a top source said.
Advertisement
ENTOD Pharmaceuticals had said: “PresVu is the first eye drop in India specifically developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition that typically impacts those over 40.”
Company CEO Nikkhil K Masurkar had claimed that PresVu was the result of years of dedicated research and development and it had secured DCGI’s approval.
Advertisement
Advertisement
Advertisement